Round Hill Asset Management Has $4.64 Million Stake in Pfizer Inc. (NYSE:PFE)

Key Points

• Round Hill Asset Management increased its stake in Pfizer Inc. by 20.4%, now holding 183,270 shares valued at approximately $4.64 million.
• Pfizer reported $0.78 earnings per share for its last quarter, exceeding analyst expectations of $0.58, with a revenue of $14.65 billion, a 10.3% increase year-over-year.
• The company is set to pay a quarterly dividend of $0.43 per share on September 2nd, yielding 6.8% with a payout ratio of 91.49%.

Round Hill Asset Management boosted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 20.4% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 183,270 shares of the biopharmaceutical company's stock after purchasing an additional 31,108 shares during the quarter. Pfizer comprises 3.3% of Round Hill Asset Management's portfolio, making the stock its 7th largest holding. Round Hill Asset Management's holdings in Pfizer were worth $4,644,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Clarity Asset Management Inc. bought a new stake in Pfizer during the fourth quarter worth approximately $27,000. Gould Capital LLC boosted its position in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares during the period. GKV Capital Management Co. Inc. bought a new stake in Pfizer during the first quarter worth approximately $27,000. Bayforest Capital Ltd bought a new stake in Pfizer during the first quarter worth approximately $28,000. Finally, North Capital Inc. bought a new stake in Pfizer during the first quarter worth approximately $28,000. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Pfizer stock opened at $25.16 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The stock has a fifty day moving average price of $24.60 and a two-hundred day moving average price of $24.44. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The firm has a market capitalization of $143.05 billion, a P/E ratio of 13.38, a P/E/G ratio of 0.89 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same period in the prior year, the company posted $0.60 earnings per share. The business's revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio is currently 91.49%.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on PFE shares. TD Cowen reduced their price objective on Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a research report on Tuesday, April 22nd. Citigroup increased their price objective on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. UBS Group increased their price objective on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Leerink Partners reduced their price objective on Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a research report on Wednesday, April 30th. Finally, Morgan Stanley increased their price objective on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, five have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.